American Association for Cancer Research

Poster Session A

Advances in Prostate Cancer Research 2012Poster Session A
Tuesday, June 19
12:30 p.m.-2:30 p.m.

In alphabetical order, not board assignment order

  • 6-Gingerol and Curcumin Suppress Pancreatic Cancer Growth by Targeting the Inhibitors of Apoptosis. Carlos Joel Diaz Osterman, Heather Ferguson, Malyn May Asuncion, Salma Khan, Nathan Wall
  • A Loss of Function Genetic Screen Identifies Determinants of Gemcitabine Sensitivity in Pancreatic Cancer. Claire W. Hardy, Brooke G. Pantazides, Khanjan Gandhi, Jerome C. Landry, Joseph W. Shelton, Shishir K. Maithel, Bassel El-Rayes, Jeanne Kowalski, David S. Yu
  • A role for leukemia inhibitory factor in oncogenic K-Ras-mediated stemness of pancreatic cancers. Man-Tzu Wang, Eric Collisson, Frank McCormick
  • Adaptive metabolic switch of pancreatic tumor cells in response to hypoxia. Fabienne Guillaumond, Sophie Vasseur, Julie Leca, Orianne Olivares, Nicolas Vidal, Jean-Pierre Cavaille, Ezequiel Calvo, Marie-Noelle Lavaut, Richard Tomasini, Juan Iovanna
  • Adiponectin deficiency enhances pancreatic cancer growth. Alisha Mendonsa, Madeleine C. Chalfant, Lee Gorden, Michael N. VanSaun
  • Altered expression of Sirtuin 1 and Deleted in Breast Cancer 1 and its functional impact on pancreatic carcinogenesis. Elke Wauters, Victor J. Sanchez-Arévalo Lobo, Andreia V. Pinho, Amanda Mawson, Luc Bouwens, Fransisco X. Real, Andrew V. Biankin, Ilse Rooman
  • Altering fibroblast integrin associated protein expression concomitantly changes the growth and protein expression of pancreas cancer cells grown in co-culture. Jill E. Shea, Kelly C. Hewitt, Courtney L. Scaife
  • Association between ambient ultraviolet radiation at birth, skin type, skin cancer history and pancreatic cancer. Rachel E. Neale, Bich Tran, David C. Whiteman, Penelope M. Webb, Lin Fritschi, Jonathan Fawcett, Harvey Risch
  • Attacking the “Achilles Heel” in the Oncogenic K-RAS Signaling Pathway to Block Tumorigenesis and Metastasis in Human Pancreatic Cancer. Amy Tang, Vasilena Zheleva, Thomas C. Smyrk, Bruce E. Knudsen, Yang Liao, Minglei Bian, Roger R. Perry, Richard A. Hoefer, Gloria M. Petersen
  • Autoantibody signature in pancreatic ductal adenocarcinoma Michela Capello, Michele Milella, Francesco Novelli, Paola Cappello, Sammy Ferri-Borgogno, Weidong Zhou, Giorgia Mandili, Claudia Fredolini, Isabella Sperduti, Federica Linty, Emanuel Petricoin
  • Can mutation profile be of help to define the cellular origin of ampullary adenocarcinoma? Marie-Claude Gingras, David Aa Wheeler, Donna M. Muzny, Sally E. Hodges, William E. Fisher, Richard A. Gibbs
  • Cancer stem cells (CSC) and inhibition of hedgehog (Hh) pathway signaling in advanced pancreatic cancer: GDC-0449 in combination with gemcitabine (Gem). Edward J. Kim, Gazala N. Khan, Kent Griffith, Joel Greenson, Naoko Takebe, Mark Zalupski, Diane Simeone
  • c-MET as a potential therapeutic target in pancreatic cancer: Implications in cancer-stem-like cell (CSC) population and gemcitabine resistance in pancreatic cancer. Amir Avan, Karl Quint, Francesco Nicolini, Mina Maftouh, Niccola Funel, Godefridus J. Peters, Elisa Giovannetti
  • Crosstalk between pancreatic stellate cells and tissue macrophages modify the tumor microenvironment in pancreatic cancer. Chanjuan Shi, Rupesh Chaturvedi, Frank Revetta, Keith T. Wilson, Mary K. Washington, Anna L. Means
  • CXCL12 and CXCR4 are reciprocally expressed in normal pancreatic ducts and pancreatic ductal adenocarcinoma respectively. Ishan Roy, Noah P. Zimmerman, Susan Tsai, Douglas B. Evans, Michael B. Dwinell
  • CXCR2 macromolecular complex in pancreatic cancer: A potential therapeutic target in tumor growth. Shuo Wang, Yanning Wu, Yuning Hou, Marcello P. Castelvetere, Xiaoqing Guan, Jacob J. Oblak , Sanjeev Banerjee, Theresa M. Filtz, Fazul H. Sarkar, Chunying Li
  • Dclk1 identifies adult pancreatic stem and cancer initiating cells. Christoph B. Westphalen, Michael Quante, Daniel L. Worthley, Samuel Asfaha, Courtney Houchen, Randal May, Helen Remotti, Kenneth P. Olive, Timothy C. Wang
  • Dendritic cells contribute to pancreatic fibro-inflammatory disease and the transition to neoplasia. Saman Zarbakhsh, Harry Mushlin, Raghavendra Rao, Sanna Badar, Mohsin Jamal, Dafna Bar-Sagi, George Miller, Adeel Rehman, Christopher Graffeo, Atsuo Ochi, Rocky Barilla, Constantinos Zambirinis, Nina Fallon, Cristina Hajdu, Yuliya Pylayeva-Gupta
  • Dicer constrains Kras driven acinar to ductal metaplasia, but is required for pancreatic ductal adenocarcinoma (PDA) formation in mice. John P. Morris, Guido von Figura, Renee VanderLaan, Anke Busch, Klemens Hertel, Holger Russ, Grace Kim, Matthias Hebrok
  • Differential processing of let-7a precursors influences gemcitabine chemosensitivity in pancreatic cancer: Role of ribonucleotide reductase subunit M2. Yangzom Bhutia, Sau Hung, Michael Thomson, Rajgopal Govindarajan
  • Distribution and significance of folate receptor β-expressing macrophages in pancreatic cancer. Sonshin Takao, Qiang Ding, Hiroshi Kurahara, Taku Nagai, Koki Maeda, Yumi Miyazaki, Kousei Maemura, Hiroyuki Shinchi, Shoji Natsugoe, Takami Matsuyama
  • Dual role of the Notch ligand Delta-1 in pancreatic carcinogenesis and metastasis. Pawel K. Mazur, Clara Lubeseder-Martellato, Barbara M. Grüner, Bence Sipos, Martin Hrabé de Angelis, Julien Sage, Roland M. Schmid, Jens T. Siveke
  • Ductal cell autophagy and oxidative stress resistance in pancreatitis and pancreatic cancer. Rengin G. Soydaner-Azeloglu, Dafna Bar-Sagi
  • Effects of alpha-Enolase silencing in adenocarcinoma pancreatic cell line. Moitza Principe, Michela Capello, Michelle Samuel Chattaragada, Weidong Zhou, Lance Liotta, Emanuel Petricoin, Francesco Novelli
  • Epigenetic loss of SLIT2 leads to an autocrine-to-paracrine switch of the SLIT2/ROBO1 signaling network in pancreatic cancer. Brenna A. Rheinheimer, Ronald L. Heimark
  • Exome sequencing identifies candidate tumor suppressor genes in familial pancreatic cancer. Robert C. Grant, Timothy Beck, Lakshmi Muthuswamy, Ayelet Borgida, Spring Holter, Stefano Serra, John McPherson, Steven Gallinger
  • Exosomal release of IAPs may contribute to chemoresistance and aggressiveness in pancreatic cancer. Malyn May Asuncion Valenzuela, Imilce V. Castro, Jonathan R. Aspe, Jonathan Neidigh, Nathan R. Wall
  • Expression of NF-ΚB p50 in pancreatic tumor stroma drives M2 differentiation and limits the control of tumors by radiation therapy. Pippa Newell, Marka Crittenden, Talicia Savage, Benjamin Cottam, Paul Hansen, Michael Gough
  • Expression of Notch-related O-linked Glycosyltransferases in Pancreatic Ductal Adenocarcinoma. Prathamesh P. Patil, Michael A Hollingsworth
  • FOXL1 suppresses tumor growth and invasiveness and predicts clinical outcome in human pancreatic ductal adenocarcinoma (PDAC). Geng Zhang, S. Perwez Hussain, Peijun He, Jochen Gaedcke, Michael B. Ghadimi, Thomas Ried, Harris G. Yfantis, Dong H. Lee, Nader Hannah, H. Richard Alexander
  • Functional characterization of gene sensitizers of pancreatic cancer cells to gemcitabine. Vikram Bhattacharjee, Timothy Yen
  • GLI1 Mediates Oncogenic KRAS Induced Transformation in Pancreatic Ductal Adenocarcinoma. Lisa Mills, Ronald Marler, Marta Herreros-Villanueva, Lizhi Zhang, Fergus Couch, Cynthia Wetmore, Martin E Fernandez-Zapico
  • Gli-dependent oncogenic activity in pancreatic tumorigenesis. Mihir Rajurkar, Wilfredo De Jesus-Monge, David Driscoll, Brian Lewis, Junhao Mao
  • Human pancreatic adenocarcinoma associated neural remodeling is regulated by intra-tumoral microenvironment. Véronique Secq, Juan Lucio Iovanna, Richard Tomasini, Atul Kumar Thakur, Noëlle Callizot, Rémy Steinschneider, Marie-noëlle Lavaut, Jérémy Nigri, Sophie Vasseur, Ezequiel Luis Calvo, Stéphane Garcia
  • HuR, an RNA binding protein, is critical for the DNA damage response in pancreatic cancer cells. Shruti Lal, Vikram Bhattacharjee, Timothy Yen, Richard A. Burkhart, Danielle M. Pineda, Charles J. Yeo, Jordan M. Winter, Isidore Rigoutsos, Jonathan R. Brody
  • Hypoxia inducible factor-1 alpha (HIF-1α) promotes migration and invasion of pancreatic cancer regulated by CD133 under hypoxia. Koki Maeda, Kosei Maemura, Shoji Natsugoe, Sonshin Takao, Qiang Ding, Makoto Yoshimitsu, Taisaku Kuwahata, Tomomi Hayashi, Shyuichiro Matsubara, Toru Obara, Yumi Miyazaki, Hiroyuki Shinchi
  • Hypoxia-activated prodrug TH-302 in combination with gemcitabine for the treatment of pancreatic adenocarcinoma: Preclinical and clinical studies. Charles P. Hart, Jessica D. Sun, Qian Liu, Dharmendra Ahluwalia, Clarence Eng, David P. Ryan, Mitesh J. Borad, Stew Kroll
  • IFT genes determine the outcome of pancreatic Kras mutations. E. Scott Seeley, Hunter Shain, Daniel Longnecker, Bradley Yoder, Gregory Pazour, Jonathan Pollack, Maxence Nachury
  • IL6 signaling is required for pancreatitis induced pancreatic intraepithelial neoplasia progression and maintenance in mice. Yaqing Zhang, Filip Bednar, Wei Yan, Meredith Anne Collins, Sabita Rakshit, Marina Pasca Di Magliano
  • Imaging heterogeneity of endogenous mouse models of pancreatic cancer. Irina Heid, Rickmer F. Braren, Marija Trajkovic-Arsic, Irene Esposito, Manuela R. Gretzinger, Andreas Steingoetter, Bernhard Haller, Markus Schwaiger, Ernst J. Rummeny, Jens T. Siveke
  • Imprime PGG®, a soluble β-1,3/1,6 immunomodulatory glucan, induces enhanced anti-tumor activity in an in vivo pancreatic tumor model when combined with cetuximab and gemcitabine. Mary A. Antonysamy, Yumi Yokoyama, Arkadiusz Z. Dudek, Nadine Ottoson, William Grossman
  • In vivo targeting of oncogenic microRNA for the therapy of pancreatic cancer. Flavie Sicard, Hubert Lulka, Louis Buscail, Pierre Cordelier
  • Inactivation of the activin signaling pathway accelerates the development of pancreatic intraductal papillary mucinous neoplasms in vivo. Wanglong Qiu, Sophia Tang, Sohyae Lee, Dario Garcia-Carracedo, Ralph H. Hruban, Helen E. Remotti, Gloria H. Su
  • Increased efficacy of oncolytic vaccinia virus, an emerging therapy for pancreatic adenocarcinoma, due to intra-tumoral hypoxia and vascular endothelial growth factor A. Crispin T. Hiley, Louisa Chard, James Tysome, Arnaud Briat, Nicholas R. Lemoine, Yaohe Wang
  • Individual variation in hENT expression in normal and malignant pancreatic tissues: The role of dietary agents in enhancing efficacy in gemcitabine treatment. Beverly Lyn-Cook, Honggang Wang, Li Pang, Beverly Word
  • Inhibiting polo-like kinases for the treatment of pancreatic cancer: Targeting kinase outliers for personalized therapy. Iris Wei, Vishal Kothari, Sunita Shankar, Shanker Kalyana-Sundaram, Catherine Grasso, Dan Robinson, Xuhong Cao, Diane Simeone, Arul Chinnaiyan, Chandan Kumar-Sinha
  • Integrative microRNA profiling of the human pancreatic cancer microenvironment identifies stromal miR-21 as a metastatic regulator predictive of poor survival. Christina Wei, Xiaojiang Xu, Luyi Li, Reginald Hill, Hong Wu, David Dawson, Timothy Donahue
  • Interfering with Ras Prenylation. Stephan C. Gysin, Cameron Pitt, Frank McCormick
  • KRAS inhibition of pancreatic beta-cell growth occurs through a MENIN-RASSF1 regulatory network. Chester E. Chamberlain, Michael S. German
  • KRAS mutational status and expressions of p53 and S100A4 proteins in pancreatic adenocarcinomas. Inger Marie Bowitz Lothe, Tone Ikdahl, Trond Buanes, Knut Jørgen Labori, Ole Petter Clausen, Gunhild M. Mælandsmo, Kjetil Boye, Tor Jacob Eide, Elin Kure
  • KRas-mediated modulation of the immune response in pancreatic neoplasia. Yuliya Pylayeva-Gupta, Kyoung Eun Lee, George Miller, Dafna Bar-Sagi
  • Localization and Identification of Pancreatic Stem Cells. Hae-Yun Jung, Sohee Jun, Jae-Il Park
  • Low dose metronomic Gemcitabine inhibits tumor growth in a pancreatic cancer model through relative supression of myeloid derived supressor cells and Bv8/PK2 expression. Erez Hasnis, Rotem Bril, Svetlana Gingis-Velitzki, Tali Voloshin, Dror Alishkevitz, Ella Fremder, Yuval Shaked
  • MALDI Imaging Mass Spectrometry for erlotinib in an endogenous mouse model for pancreatic cancer. Barbara M. Gruener, Evdokia Kalideris, Isabel Winkelmann, Annette Feuchtinger, Benjamin Balluff, Sandra Rauser, Roland M. Schmid, Axel Walch, Jens T. Siveke
  • Meta-analysis of nine pancreatic cancer data sets identifies novel serum biomarkers. Purvesh Khatri, Maneesha Limaye, Yuri Kim, Albert Koong, Atul J. Butte
  • Metformin targets human pancreatic cancer stem cells in preclinical mouse models. Enza Lonardo, Michele Cioffi, Yolanda Sanchez, Jorge Dorado, Christopher Heeschen
  • Minnelide, a potent chemotherapeutic agent, causes pancreatic tumor regression. Veena Sangwan, Rohit Chugh, Satish P. Patil, Gunda I. Georg, Selwyn M. Vickers, Ashok K. Saluja
  • MM-141, a novel tetravalent bispecific antibody directed at IGF-1R and ErbB3 that inhibits pancreatic tumor cell growth and potentiates the effects of gemcitabine. Bryan Johnson, Yang Jiao, Birgit Schoeberl, Ulrik Nielsen, Jonathan Fitzgerald, Alexey Lugovskoy, Sharlene Adams, Jason Baum, Jian Tang, Sergio Iadevaia, Neeraj Kohli, Rachel Rennard, Pragalath Sundararajan, Lihui Xu
  • MM-398/PEP02, a novel liposomal formulation of irinotecan demonstrates stromal-modifying anti-cancer properties. Nancy Paz, Peter Laivins, Clet Niyikiza, Ulrik Nielsen, Jonathan Fitzgerald, Ashish Kalra, Milind Chalishazar, Stephan Klinz, Jaeyeon Kim, Daryl Drummond, Dmitri Kirpotin, Victor Moyo, Eliel Bayever
  • Neuroplastic changes and pain-related behavior in a transgenic mouse model of pancreatic ductal adenocarcinoma (PDAC). Rachelle E. Stopczynski, Kathryn M. Albers, Klaus Bielefeldt, Ronald A. DePinho, Haoqiang Ying, Brian M. Davis
  • Novel anti-HER3 strategy for pancreatic cancer therapy. Donald J. Buchsbaum, Xian Chen, Enyun Shen, Tong Zhou
  • Oncogenic Kras is required for pancreatic tumor maintenance through the regulation of anabolic glucose metabolism. Costas Lyssiotis, Haoqiang Ying, Alec Kimmelman, Ronald DePinho, Lewis Cantley
  • Oncogenic Kras Maintains Pancreatic Tumors through Regulation of Anabolic Glucose Metabolism. Haoqiang Ying, Hailei Zhang, Jonathan L. Coloff, Haiyan Yan, Wei Wang, Shujuan Chen, Andrea Viale, Hongwu Zheng, Ji-hye Paik, Carol Lim, Alexander R. Guimaraes, Alec C. Kimmelman, Eric S. Martin, Jeffery Chang, Aram Hezel, Samuel R. Perry, Jian Hu, Boyi Gan, Yonghong Xiao, John M. Asara, Ralph Weissleder, Y. Alan Wang, Costas A. Lyssiotis, Lynda Chin, Lewis C. Cantley, Ronald A. DePinho, Sujun Hua, Gerald C. Chu, Eliot Fletcher-Sananikone, Jason W. Locasale, Jaekyoung Son
  • Oncogenic ras requires stimulation for activity sufficient to initiate a feed-forward inflammatory mechanism capable of inducing pancreatic diseases including pancreatitis and cancer. Baoan Ji, Huamin Wang, Haojie Huang, Craig D. Logsdon
  • Overexpression of Wnt1 induces ovarian-type stroma that resemble to human pancreatic mucinous cystic neoplasm (MCN). Makoto Sano, David Driscoll, David S. Klimstra, Wilfredo DeJesus-Monge, Victoria Appleman, Brian Quattrochi, Brian C. Lewis
  • PAR-2 activation with ATP facilitation induces migration but not proliferation of pancreatic cancer cells. Kun Shi, Karla CS Queiroz, C. Arnold Spek
  • Phase I trial of EUS-guided intratumoral vaccination with recombinant Panvac-F and systemic Panvac-V in patients with locally advanced pancreatic cancer. Elizabeth A. Poplin, Edmund C. Lattime, David A. August, Tamir Ben-Menachem, Hazar Michael, Aparna Repaka, Renee Artymyshyn, James L. Gulley, Jeffrey Schlom, Robert S DiPaola
  • Phase I Trial of Radiotherapy with Concurrent Bevacizumab, Erlotinib and Capecitabine for Locally Advanced Pancreatic Cancer (LAPC). Heath D. Skinner, Christopher H. Crane, Sunil Krishnan, Milind M. Javle, Robert A. Wolff, Jason B. Fleming, Marilyn V. Clemons, Mark F. Munsell, Marc E. Delclos, Prajnan Das
  • Plectin trafficking in oncosomes contributes to pancreatic cancer proliferation and invasion. Soo J. Shin, Jeffrey A. Smith, Günther Rezniczek, Gerhard Wiche, Kimberly A. Kelly
  • Post-transcriptional gene regulation by HuR can explain metabolic reprogramming in acutely stressed pancreatic cancer cells. Jordan M. Winter, Rick A. Burkhart, Joseph Cozzitorto, Charles J. Yeo, Jonathan R. Brody
  • Pre-existing immune responses against EGFR, Her-2, Bcl-2, survivin, Wnt-1 and Sox2 in pancreatic cancer patients. Jose V. Torres, Gardner B. Murray, Ramon Cabello, Eduardo Flores, Alejandro Camacho, Pedro A. Lucero, Anton Ostashko, Roger Dela Cruz Jr, Fernando Durazo, Xia Li, Lizette Rodriguez, Erik Ramos, Juan Pablo Marquez-Manriquez
  • Prospects for developing a biomarker panel for accurate detection of pancreatic adenocarcinoma. Matthew A. Firpo, Kenneth M. Boucher, Sean J. Mulvihill
  • Protease-activated receptor-1 (PAR-1) supports pancreatic cancer progression and drug resistance. Karla C.S. Queiroz, Kun Shi, C. Arnold Spek
  • Prox1-happloinsufficiency contributes to the transforming effects of Kras in the pancreas. Yiannis Drosos, Jianming Ye, David Finkelstein, Jerold Rehg, Anirban Maitra, Anna Means, Ramon Klein Geltink, Gerard Grosveld, Beatriz Sosa-Pineda
  • Radiation-Induced Phosphorylation of ATDC via ATM/ MAPKAP kinase 2 Signaling Mediates Radioresistance of Pancreatic Cancer Cells. Lidong Wang, Theodore Lawrence, Liang Xu, Chris Canman, Mats Ljungman, Diane Simeone, Huibin Yang, Phillip Palmbos, Gina Ney, Taylor Ann Detzler, Dawn Coleman, Mary Davis, Kevin Hicks, Corey M. Helchowski
  • Reciprocal dialogue between cellular and extracellular matrix tension and tissue inflammation in pancreatic tumor progression. Hanane Laklai, Raghu Kalluri, Harold Moses, Valerie Weaver, Hideaki Ijichi, Jonathan Lakins, Yekaterina Miroshnikova, Irene Acerbi, Jose Lopez, Elena Kassianidou, Agnieszka Gorska, Sergey Novitskiy
  • Reduced expression of histone demethylase KDM6B promotes pancreatic cancer progression through downregulation of C/EBPα. Keisuke Yamamoto, Keisuke Tateishi, Yotaro Kudo, Miwako Kakiuchi, Shinzo Yamamoto, Kouji Miyabayashi, Yoshinari Asaoka, Hideaki Ijichi, Masao Omata, Kazuhiko Koike
  • Regulation and Role of NF-ΚB in Pancreatic Cancer. Peter Storz
  • Rgs16: HTS biomarker for pancreas development, diabetes and PDAC. Thomas M. Wilkie, Ozhan Ocal, Lee B. Rivera, Rolf A. Brekken
  • Role of vitamin D receptor (VDR) gene polymorphisms for overall survival in pancreatic cancer: Genome-wide association and functional mechanistic studies. Innocenti Federico, Alan P. Venook, Howard L. McLeod, Yusuke Nakamura, Mark J. Ratain, Gloria M. Petersen, William R. Bamlet, Robert R. McWilliams, Kouros Owzar, Dylan M. Glubb, Chen Jiang, Nancy J. Cox, Michiaki Kubo, Hitoshi Zembutsu, Taisei Mushiroda, Hedy L. Kindler
  • Screening for kinase inhibitors that sensitize pancreatic cancer cells to gemcitabine: Is collateral damage a good thing? Neil Beeharry, Timothy Yen
  • SIAH2-mediated proteolysis of LIM domain proteins induces invasion and metastasis in response to oncogenic K-RAS activation in human pancreatic cancer cells. Amy H. Tang, Yang Liao, Rebecca L. Schmidt, Zandra E. Walton, Rie Takahashi
  • Small molecule (LWKS22) drug discovery for pancreatic cancer therapy. Yan Wang, Angela Echaverri, Anastasia Warde, Thiru Arumugham, Kit Lam, Pappanaicken Kumaresan
  • Strategies to combat hypoxia driven PDAC invasion after anti-angiogenic therapy. Lee B. Rivera, Juliet G. Carbon, Kristina Aguilera, Jason E. Toombs, Amanda Kirane, Michael T. Dellinger, Gaurab Chakrabarti, Jordan Braunfeld, Rolf A. Brekken
  • Surveying the serum proteome for early-stage pancreatic neoplasia biomarkers using genetically engineered mouse models. Michael R. Ludwig, Kyoko Kojima, Nirag C. Jhala, William E. Grizzle, John D. Christein, Christopher A. Klug, James A. Mobley
  • Survivin-T34A enhances Gemcitabine treatment in pancreatic cancer. Jonathan R. Aspe, Simone DeShields, Nathan R. Wall
  • Sustained intratumoral activation of MM-398 results in superior activity over irinotecan demonstrated by using a systems pharmacology approach. Jaeyeon Kim, Eliel Bayever, Peter Laivins, Clet Niyikiza, Ulrik Nielsen, Jonathan Fitzgerald, Ashish Kalra, Milind Chalishazar, Stephan Klinz, Nancy Paz, Bart Hendriks, Daryl Drummond, Dmitri Kirpotin, Victor Moyo
  • Targeted Therapy for Pancreatic Cancer. Kathryn Leake, Sharad S. Singhal, Sanjay Awasthi
  • Targeting Tumor Hypoxia in Patient-Derived Pancreatic Xenografts Using TH-302. Ines Lohse, Joanna Rasowski, PinJiang Cao, Emin Ibrahimov, Melania Pintille, Ming S. Tsao, Richard Hill, David W. Hedley
  • Targeting Wee1 in primary pancreatic cancer xenografts. Qing Chang, Jason Moffat, David W. Hedley
  • TH17 cells in early pancreatic tumorigenesis. Florencia McAllister, Jay K. Kolls, Charles G. Drake, Drew M. Pardoll, Steven D. Leach, Jennifer M. Bailey, Janivette Alsina, Christopher Nirschl, Jeffrey C. Roeser, Danielle Blake, Cynthia L. Sears, Elizabeth M. Jaffee
  • The chromatin regulator Brg1 suppresses the formation of intraductal papillary mucinous neoplasm in the context of oncogenic Kras. Guido von Figura, Anke Busch, Klemens J. Hertel, Matthias Hebrok, Akihisa Fukuda, Muluye E. Liku, John P. Morris, Grace E. Kim, Holger A. Russ, Matthew A. Firpo, Sean J. Mulvihill, William F. Mueller
  • The deubiquitinase USP9X suppresses pancreatic ductal adenocarcinoma. Pedro A. Perez-Mancera, David A. Tuveson, Alistair G. Rust, Andrew V. Biankin, Lodewyk F.A. Wessels, Stephen A. Wood, Christine A. Iacobuzio-Donahue, Christian Pilarsky, David A. Largaespada, David J. Adams
  • The exploration of novel strategy for treatment of pancreactic ductal adenocarcinoma targeting tumor microenvironment. Motohisa Tada, Masao Omata, Harold L. Moses, Osamu Yokosuka, Hideaki Ijichi, Koji Miyabayashi, Yoshinari Asaoka, Dai Mohri, Tsuneo Ikenoue, Rintarou Mikata, Takeshi Ishihara, Fumihko Kanai
  • The extracellular matrix regulates pancreatic cancer stem cell function via focal adhesion kinase signaling. Zeshaan A. Rasheed, Clinton Jung, Ally Huang, Jessica Norberg, N.V. Rajeshkumar, Anirban Maitra, William Matsui
  • The Id3 /E47 axis orchestrates growth versus differentiation in pancreatic cancer and exocrine pancreas development. Chelsea Riha, Challeng Yang, Keith Gates, P.D. Dong, Pamela Itkin-Ansari
  • The marine natural product manzamine A targets vacuolar ATPases and autophagy in pancreatic cancer cells. Georgios Kallifatidis, Dominic Hoepfner, Sven Schuierer, Nicole Hartmann, Esther Guzmán, Amy Wright
  • The pancreatic ductal adenocarcinoma project at the Ontario Institute for Cancer Research. Kimberly N. Begley, Debabrata Mukhopadhyay, Gloria M. Petersen, Alexei Protopopov, Sarah Thayer, Lynda Chin, Emin Ibrahimov, Patricia Shaw, Thomas Hudson, Steve Gallinger, Ming-Sound Tsao, Lincoln Stein, John D. McPherson, Lakshmi Muthuswamy, Timothy Beck, Christina Yung, Michelle Sam, Lee Timms, Carson Holt
  • The Prrx1 Homeodomain Transcription Factor Plays a Central Role in Pancreatic Regeneration and Carcinogenesis. Maximilian Reichert, Anil K. Rustgi, Shigetsugu Takano, Johannes A. von Burstin, Steffen Heeg, Gregory P. Botta, Ju-Seog Lee, Gunter Schneider, Andrew D. Rhim, Ben Z. Stanger
  • The role of the Cancer-associated Sm-like oncogene in development of pancreatic cancer. Elizabeth C. Little, E. Ramsay Camp, Cindy Wang, Patricia M. Watson, Dennis K. Watson, David J. Cole
  • Translational control of pancreatic carcinogenesis. Yvan Martineau, Sally Khawand, Charline Lasfargues, Rania Azar, Corinne Bousquet, Stéphane Pyronnet
  • Truncated O - glycans Enhance Tumorigenicity of Pancreatic Tumors. Prakash Radhakrishnan, James A. Grunkemeyer, Henrik Clausen, Michael A. Hollingsworth
  • Validation of candidate serum biomarkers demonstrates the potential of CUZD1 and LAMC2 to complement CA19.9 for pancreatic cancer diagnosis. Caitlin Chrystoja, Hari Kosanam, Ioannis Prassas, Alison Chan, Apostolos Dimitromanolakis, Shalini Makawita, Antoninus Soosaipillai, Ivan Blasutig, Eleftherios P. Diamandis
  • WD-repeat containing transcriptional co-factors as molecular links between diabetes, obesity and pancreatic cancer. Christian Stoy, Oliver Strobel, Jens Werner, Stephan Herzig
Poster
Session A
Poster
Session B